{"title":"Comparison of splenic embolization and splenectomy for traumatic splenic rupture: a meta-analysis.","authors":"Feng-Fei Xia, Quan-Kui Li, Yi Zhang","doi":"10.1080/13645706.2024.2372308","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>This study aims to assess the safety and clinical efficacy of percutaneous splenic embolization (PSE) and splenectomy as approaches to treating cases of traumatic splenic rupture (TSR).</p><p><strong>Material and methods: </strong>Eligible articles published throughout August 2023 were identified. Endpoints compared between PSE and splenectomy patient groups included operative time, intraoperative hemorrhage, duration of hospitalization, postoperative complication rates, and measures of immune function.</p><p><strong>Results: </strong>Thirteen studies, involving 474 and 520 patients in the PSE and splenectomy groups respectively, were incorporated into this meta-analysis. As compared to the splenectomy group, individuals treated <i>via</i> PSE exhibited a significant reduction in pooled operative time (<i>p</i> < 0.00001) and hospitalization duration (<i>p</i> < 0.00001), with corresponding reductions in rates of intraoperative hemorrhage (<i>p</i> < 0.00001), total complications (<i>p</i> < 0.0001), incisional infection (<i>p</i> < 0.0001), ileus (<i>p</i> = 0.0004), and abdominal infection (<i>p</i> = 0.02). The immune status of these PSE group patients was also improved, as evidenced by significantly higher pooled CD4<sup>+</sup> (30 days), CD4<sup>+</sup>/CD8<sup>+</sup> (30 days), and CD3<sup>+</sup> (30 days) values (<i>p</i> < 0.0001, 0.0001, and 0.0001, respectively).</p><p><strong>Conclusions: </strong>Compared to splenectomy, PSE-based TSR treatment can significantly reduce operative time, rate of postoperative complications, and incidence of intraoperative hemorrhage, while improving post-procedural immune functionality.</p>","PeriodicalId":18537,"journal":{"name":"Minimally Invasive Therapy & Allied Technologies","volume":" ","pages":"278-286"},"PeriodicalIF":1.7000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minimally Invasive Therapy & Allied Technologies","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/13645706.2024.2372308","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: This study aims to assess the safety and clinical efficacy of percutaneous splenic embolization (PSE) and splenectomy as approaches to treating cases of traumatic splenic rupture (TSR).
Material and methods: Eligible articles published throughout August 2023 were identified. Endpoints compared between PSE and splenectomy patient groups included operative time, intraoperative hemorrhage, duration of hospitalization, postoperative complication rates, and measures of immune function.
Results: Thirteen studies, involving 474 and 520 patients in the PSE and splenectomy groups respectively, were incorporated into this meta-analysis. As compared to the splenectomy group, individuals treated via PSE exhibited a significant reduction in pooled operative time (p < 0.00001) and hospitalization duration (p < 0.00001), with corresponding reductions in rates of intraoperative hemorrhage (p < 0.00001), total complications (p < 0.0001), incisional infection (p < 0.0001), ileus (p = 0.0004), and abdominal infection (p = 0.02). The immune status of these PSE group patients was also improved, as evidenced by significantly higher pooled CD4+ (30 days), CD4+/CD8+ (30 days), and CD3+ (30 days) values (p < 0.0001, 0.0001, and 0.0001, respectively).
Conclusions: Compared to splenectomy, PSE-based TSR treatment can significantly reduce operative time, rate of postoperative complications, and incidence of intraoperative hemorrhage, while improving post-procedural immune functionality.
导言:本研究旨在评估经皮脾栓塞术(PSE)和脾切除术作为治疗创伤性脾破裂(TSR)病例的方法的安全性和临床疗效:对2023年8月期间发表的符合条件的文章进行了鉴定。PSE和脾切除术患者组之间比较的终点包括手术时间、术中出血量、住院时间、术后并发症发生率和免疫功能测量:本次荟萃分析共纳入了 13 项研究,分别涉及 PSE 组和脾脏切除术组的 474 名和 520 名患者。与脾脏切除术组相比,通过 PSE 治疗的患者的总手术时间(p p p p p = 0.0004)和腹腔感染(p = 0.02)显著缩短。这些 PSE 组患者的免疫状况也得到了改善,表现为集合 CD4+(30 天)、CD4+/CD8+(30 天)和 CD3+(30 天)值明显升高(p 结论:PSE 组患者的免疫状况明显改善:与脾切除术相比,基于 PSE 的 TSR 治疗可显著缩短手术时间、降低术后并发症发生率和术中出血发生率,同时改善术后免疫功能。
期刊介绍:
Minimally Invasive Therapy and Allied Technologies (MITAT) is an international forum for endoscopic surgeons, interventional radiologists and industrial instrument manufacturers. It is the official journal of the Society for Medical Innovation and Technology (SMIT) whose membership includes representatives from a broad spectrum of medical specialities, instrument manufacturing and research. The journal brings the latest developments and innovations in minimally invasive therapy to its readers. What makes Minimally Invasive Therapy and Allied Technologies unique is that we publish one or two special issues each year, which are devoted to a specific theme. Key topics covered by the journal include: interventional radiology, endoscopic surgery, imaging technology, manipulators and robotics for surgery and education and training for MIS.